{
    "2020-06-07": [
        [
            {
                "time": "",
                "original_text": "康泰生物实控人“天价”离婚背后：业绩高速增长已不再",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "实控人",
                        "天价离婚",
                        "业绩",
                        "高速增长"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|周报】：疫苗集中采购政策对疫苗价格和量影响很有限，持续关注后疫情时代下“枢纽性”和内需驱动型板块的成长确定性",
                "features": {
                    "keywords": [
                        "民生医药",
                        "疫苗",
                        "集中采购",
                        "政策",
                        "后疫情时代",
                        "枢纽性",
                        "内需驱动",
                        "成长确定性"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}